METABOLIC DISORDERS
Combined parathyroid hormone+alendronate therapy versus PTH monotherpy for osteoporosis
J Invest Surg. 2015 Dec;28(6):309-166 randomized controlled trials, including a total of 833 patients, were analyzed to evaluate the efficacy of combined parathyroid hormone (PTH) and alendronate administration in the treatment of osteoporosis. The meta-analysis assessed mean percent increases in bone mineral density (BMD) at the lumbar spine, femoral neck, total hip, and distal radius with combination therapy compared to monotherapy of PTH or teriparatide alone. Results demonstrated no significant differences between combined and monotherapy groups for percent changes in BMD of the lumbar spine, femoral neck, or total hip. Distal radius BMD was observed to significantly increase with combined therapy versus monotherapy.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
